Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Gui…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.58 | $-0.59 | $-0.63 |
| Estimado | $-0.32 | $-0.40 | $-0.55 | $-0.56 |
| Sorpresa | — | -45.0% | -7.3% | -12.5% |
| Métrica | NYXH | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 63.1% | 57.4% | +5.7% |
| Operating Margin | -833.2% | -34.4% | -798.8% |
| Net Margin | -899.0% | -32.5% | -866.6% |
| FCF Margin | -696.5% | -12.6% | -683.9% |
| ROE | -183.4% | -39.2% | -144.2% |
| ROA | -76.0% | -30.9% | -45.1% |
| Current Ratio | 1.25 | 2.73 | -1.48 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -76.0% | — |
| ✗Flujo de caja operativo positivo | −€69M | −€49M |
| ✗Rentabilidad sobre activos al alza | -76.0% | -37.4% |
| ✓Caja operativa/activos supera al ROA | -58.2% | ROA -76.0% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 1.25 | 4.56 |
| ✗Sin aumentar el nº de acciones | 38M | 33M |
| ✗Margen bruto al alza | 63.1% | 65.7% |
| ✓Rotación de activos al alza | 0.08 | 0.03 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -696.5% |
| ✗ROCE > 10 % | -120.1% |
| ✓Ventas > 5 %/año (3 años) | 48.1% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 435.4% |
Nyxoah SA cotiza a 1.11 USD y tiene una capitalización bursátil de $113M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud